

MICROGEN DIAGNOSTICS

2002 W LOOP 289, SUITE 116 | LUBBOCK, TX 79407 FAX: 1 - 407 - 204 - 1401 | PHONE: 1 - 855 - 208 - 0019

PATIENT	PATIENT NAME	SPECIMEN	RT NASAL	PHYSICIAN	Pandit, Rajiv
DOB	MM/DD/YYYY	RECEIVED	MM/DD/YYYY	PHONE	(###)###-####
PATIENT ID	PATIENT ID	COMPLETED	MM/DD/YYYY	FAX	(###)###-####
GENDER	Female	ACCESSION	ACCESSION #	COLLECTED	MM/DD/YYYY

RESISTANCE GENES DETECTED

None

		-				ΑN	ITIN	IICR	ROB	IAL	RE	COI	ИМЕ	END	ATI	ON		
LEVEL 2 NGS REPORT					Avycaz	Aminoglycosides	Fluoroquinolo	Metronidazole (Flagyl)	Clindamycin	Extended spe lactamase inh	Penicillins e.g. Penicillin	Aminopenicilli	Carbapenems e.g. Merrem					
COMPREHENSIVE IDENTIFICATION NEXT-GEN DNA SEQUENCING RESULTS with PRIOR PCR RESULTS.			Gram Stain	Respiration		des e.g. Amikacin	Fluoroquinolones e.g. Levofloxacin	(Flagyl)		Extended spectrum penicillins/Beta- lactamase inhibitors e.g. Augmentin	. Penicillin	Aminopenicillins e.g. Ampicillin	e.g. Merrem					
,	DNA copies (N/A)	NGS	Stai	atio														
BACTERIAL LOAD	High	%	3	Š	IV	IV	PO	РО		PO	PO	РО						
Pseudomonas aeruginosa	Medium	89%	-	Ae	1	√	√											
Parvimonas micra	UnkBL	5%	+	An				\checkmark	√	√								
Prevotella sp	UnkBL	2%	-	An			√	√	√	√	1	√						
Peptostreptococcus stomatis	UnkBL	2%	+	An	1				√	√	1		V					
FUNGI DETECTED		%		I			AN1	ΓIFU	NG	AL I	REC	OM	MF	ND/	ATIC	NC		
None		,,				<u> </u>				_ _ '								

	EADIN	El Olli Rei	
DNA copies per g:	Gram Stain:	Respiration:	Antimicrobial:
[UnkBL] = Unknown Bacterial Load	[+] = Positive	[Ae] = Aerobic	[V] = Proven to be effective.
Bacterial Load: < 10 ⁵ = LOW	[-] = Negative	[An] = Anaerobic	[R] = Resistance genes detected.
10 ⁵ to 10 ⁷ = MED	[I] = Indeterminate	[Fan] = Facultative anaerobic	[]=Empty Fields denote Unknown.
> 10 ⁷ = HIGH	[N] = Not Applicable;	[Unk] = Unknown	[PO]= Available in Oral formulations.
	[U] = Unknown		[IV] = Intravenous; [TP] = Topical.
	•	•	•

all



MICROGEN DIAGNOSTICS

2002 W LOOP 289, SUITE 116 | LUBBOCK, TX 79407 FAX: 1 - 407 - 204 - 1401 | PHONE: 1 - 855 - 208 - 0019

PATIENT	PATIENT NAME	SPECIMEN	RT NASAL	PHYSICIAN	Pandit, Rajiv
DOB	MM/DD/YYYY	RECEIVED	MM/DD/YYYY	PHONE	(###)###-####
PATIENT ID	PATIENT ID	COMPLETED	MM/DD/YYYY	FAX	(###)###-####
GENDER	Female	ACCESSION	ACCESSION #	COLLECTED	MM/DD/YYYY

qPCR TESTS FOR THE FOLLOWING BACTERIA			FUNGI	STIs	RESISTA	NCE GENES
Streptococcus agalactiae	Streptococcus pyogenes	Pseudomonas aeruginosa	Candida albicans	None	Vancomycin	Methicillin
Staphylococcus aureus	Haemophilus influenzae	Moraxella catarrhalis			Beta-lactam	Aminoglycoside
Streptococcus pneumoniae					Tetracycline	Carbapenem
					Macrolide	Quinolone

Next Generation Sequencing Results

MicroGen Diagnostics' comprehensive testing (patent pending) is a relative quantitative universal test for bacteria/fungi. DNA sequencing methods are used to identify the microorganisms' genetic signatures and the estimated percentage of organisms present in the specimen. Virtually all bacteria/fungi are screened for and the most predominant populations are reported.

ANTIBIOTIC CLASSES AND MOST-COMMONLY USED EXAMPLES								
CLASS	GENERIC formulations	CLASS	GENERIC formulations					
Allylamines	Amorolfine; Naftifine	Flucytosine	5-fluorocytosine (Ancobon)					
Aminoglycosides	Gentamycin; Tobramycin	Fluoroquinolones	Norfloxacin(PO); Levofloxacin;					
Aminoglycosides+Aminopenicillins	Ampicillin/Gentamicin		Oxafloxacin(PO)					
Aminopenicillins	Amoxicillin; Ampicillin(PO)	Glycopeptides	Vancomycin; Teicoplanin					
Antifolates	TMP/SMX	Imidazoles	Ketoconazole(PO); Clotrimazole;					
Anti-Pseudomonal Penicillins	Piperacillin; Nafcillin		Oxiconazole					
Anti-Pseudomonal penicillins/Beta-	Piperacillin/Tazobactam	Lipopeptides	Daptomycin					
lactamase inhibitors		Macrolides	Erythromycin; Azithromycin(PO)					
Anti-tuberculosis	Isoniazid; Rifampin; Streptomycin	Naphthyridones	Nalidixic acid					
Aztreonam	Azactam	Oxacephems	Moxalactam					
Carbapenems	Cilistatin/Imipenem; Meropenem	Penicillins	Penicillin G; Penicillin V(PO)					
Cephalosporins First Gen	Cephalexin(PO); Cefazolin	Polyenes	Natamycin; Amphotericin B					
Cephalosporins Fourth Gen	Cefepime	Polyenes+Flucytosine	Amphotericin B/5-fluorocytosine					
Cephalosporins Second Gen	Cefprozil; Cefotetan	Quinolones	Ciprofloxacin (PO); Levofloxacin;					
Cephalosporins Third Gen	Cefixime; Cefdinir; Ceftazidime		Moxifloxacin(PO)					
Cephamycins	Cefoxitin	Tetracyclines	Doxycycline(PO); Minocycline					
Echinocandins	Caspofugin; Micafungin	Triazoles	Fluconazole(PO); Terconazole					
Extended spectrum penicillins /	Amoxicillin / Clavulanate(PO);	Triazoles+Echinocandins	Voriconazole/Anidulafungin					
Beta-lactamase inhibitors	Ampicillin / Sulbactam							

Complete Antibiotic Analysis

ANTIBIOTIC DISCLAIMER: Southwest Regional PCR, DBA MicroGen Diagnostics, LLC assumes no liability to patients with respect to the actions of physicians, health care facilities and other users, and is not responsible for any injury, death or damage resulting from the use, misuse or interpretation of information obtained through this antibiotic report. Therapeutic options listed by the program are based upon national antibiotic susceptibility data and antibiograms. Therapy should not be undertaken without a thorough assessment of the indications, contraindications and side effects of any prospective drug or intervention. Furthermore, the database is curated and derived from incidence and prevalence statistics whose accuracy will vary widely for individual diseases and regions of the country. Changes in endemicity, incidence, and drugs of choice may occur. The list of drugs, infectious diseases and even country names will vary with time. Although we endeavor to include such new information on a timely basis, a delay cannot be avoided. For more information please contact us at 855-208-0019.

DISCLAIMER: (i)This test was developed and performance characteristics have been determined by Southwest Regional PCR Laboratory dba MicroGen DX. It has not been cleared or approved by the U.S.Food and Drug Administration(FDA), however, the FDA has determined that such clearance or approval is not necessary. This test is used for clinical purposes. Its use should not be regarded as investigational or for research. This laboratory is certified under the Clinical Laboratory tory improvement Amendments of 1988(CLIA 88) as qualified to perform high complexity clinical laboratory testing. (ii) A negative result does not rule out the presence of PCR inhibitors, or DNA extraction inhibitors such as lidocaine, in patients' specimens or microbial DNA concentrations below the level of detection of the assay. (iii) This test is performed pursuant to an agreement with Roche Molecular Systems, Inc. (iv) Relative quantitation of swabs refers to analyte load levels of < 10⁵, 10⁵ to 10⁷, and > 10⁷ for low, medium and high respectively.

ANTIBIOTIC ANALYSIS

This antimicrobial recommendation sheet is not based on antibiotic sensitivities but is based on antimicrobial reference guides such as the John Hopkins ABX Guide.

all